Few modern targeted therapies for HPV(−) HNSCC have emerged, and the approved therapies targeting EGFR [20] and the PD1/PDL1 axis [21] have had limited overall impact on treatment outcomes. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.